| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 04/23/2003 | EP1303305A2 Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure |
| 04/23/2003 | EP1303304A2 Pharmaceutical combinations for treatment and prevention of diabetes mellitus |
| 04/23/2003 | EP1303296A1 Composition containing an iron complexing protein and a precursor of nitrogen monoxide metabolism and/or a chemical donor of nitrogen monoxide and uses thereof |
| 04/23/2003 | EP1303284A1 Compositions and methods for the treatment of skin damage |
| 04/23/2003 | EP1303273A1 New pharmaceutical composition and the process for its preparation |
| 04/23/2003 | EP1303271A1 Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug |
| 04/23/2003 | EP1303268A1 Highly purified simvastatin compositions |
| 04/23/2003 | EP1303266A1 Treatment of eating disorders using carboxyalkylethers |
| 04/23/2003 | EP1250055A4 Immune modulation with death receptor-induced apoptosis |
| 04/23/2003 | EP1222183B1 Benzopyran derivatives |
| 04/23/2003 | EP1220863B1 Purine derivatives |
| 04/23/2003 | EP1218378B1 Tert.-butyl-(7-methyl-imidazo[1,2-a]pyridine-3-yl)-amine derivatives |
| 04/23/2003 | EP1196050B1 Compositions for providing and maintaining energy and mental alertness |
| 04/23/2003 | EP1185175B1 Method of increasing the content of flavonoids and phenolic substances in plants |
| 04/23/2003 | EP1107744B1 Use of substance p antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia |
| 04/23/2003 | EP1102739B1 Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders |
| 04/23/2003 | EP1082314B1 New dipeptidyl peptidase iv effectors |
| 04/23/2003 | EP0797443B1 A pharmaceutical composition with improved bio-availability of inositol phosphate |
| 04/23/2003 | EP0787725B1 Quinoline derivative |
| 04/23/2003 | EP0699072B1 Use of iron-binding polymers for the manufacture of a medicament for oral administration |
| 04/23/2003 | CN1413250A Method of producing differentiated progenitor cells and lineage-defective embryonic stem cells |
| 04/23/2003 | CN1413213A Azaindoles |
| 04/23/2003 | CN1413210A Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases |
| 04/23/2003 | CN1413207A 5-membered ring heterocyclic compounds with nitrogen |
| 04/23/2003 | CN1413206A Non peptide tachykinin receptor antagonists |
| 04/23/2003 | CN1413197A 4-phenyl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
| 04/23/2003 | CN1413192A Substituted indole mannich bases |
| 04/23/2003 | CN1413185A Substitued 1 and 2 naphthol mannich bases |
| 04/23/2003 | CN1413184A Novel compounds to treat diabetes and associated conditions |
| 04/23/2003 | CN1413107A Use of hypoglycemic agent for treating impaired clucose metabolism |
| 04/23/2003 | CN1413105A Novel method of treatment |
| 04/23/2003 | CN1412181A Carboxylic acid derivative capable of inhibiting combination of integrin and its receptor |
| 04/23/2003 | CN1411869A Body-strengthening nutrient sour liquor, preparation method and application |
| 04/23/2003 | CN1411860A Tianqi sugar-reducing capsule |
| 04/23/2003 | CN1411847A Gushen sugar-reducing pill |
| 04/23/2003 | CN1411844A Weight-reducing Chinese medicine acted on acupoint |
| 04/23/2003 | CN1411843A Serier compound Chinese herbal medicine pure natural high-calcium preparation |
| 04/23/2003 | CN1411838A Medicine for curing diabetes |
| 04/23/2003 | CN1411833A Pure Chinese medicine preparation |
| 04/23/2003 | CN1411812A Oral medicine preparation with high absorbency |
| 04/23/2003 | CN1411810A Fatigue-resistant drug composition |
| 04/23/2003 | CN1411809A Usage and composition of pyridine onium derivative for curing application |
| 04/23/2003 | CN1411800A Cosmetic composition and method |
| 04/23/2003 | CN1411733A Health-care tea capable of reducing fat, reducing weight and clearing heat away |
| 04/23/2003 | CN1106384C Indoline-2-one derivatives, its preparing method and its medicinal compositions |
| 04/23/2003 | CN1106380C New synthetic catechol derivatives, method for production and use thereof |
| 04/23/2003 | CN1106195C Use of thazolinedione derivatives and related antihyperglycemic agents in treatment of disease states at risk for progressing to non-insulin-dependent diabetes mellitus |
| 04/23/2003 | CN1106193C Anticonvulsant sulfamate derivs. useful in treating obesity |
| 04/23/2003 | CA2403307A1 Substituted 2-cyclohexyl-4-phenyl-1h-imidazole derivatives |
| 04/22/2003 | US6552225 Such as n-(2,3-dichloro-4-(methylaminosulphonyl)phenyl)-3,3,3-trifluoro-2-hydroxy-2 -methylpropanamide; diabetes, obesity, lactic acidaemia |
| 04/22/2003 | US6552223 N-hydroxacylamino compounds, process for their preparation and pharmaceutical compositions containing them |
| 04/22/2003 | US6552216 Molecular model for VLA-4 inhibitors |
| 04/22/2003 | US6552202 Crystal form of N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide |
| 04/22/2003 | US6552168 Inhibition of apoptosis via attenuation of caspase activity should therefore be useful in the treatment of human diseases where inappropriate apoptosis is prominent or contributes to disease pathogenesis |
| 04/22/2003 | US6552077 Kidney disorders |
| 04/22/2003 | US6552062 For therapy of central nervous system disorders; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea, and obesity |
| 04/22/2003 | US6552058 Oxazolidinedione derivatives and their use |
| 04/22/2003 | US6552049 Antidepressant azaheterocyclylmethyl derivatives of oxaheterocycle-fused-[1,4]-benzodioxans |
| 04/22/2003 | US6552048 Sulfonylcarboxamide derivatives, process for their preparation and their use as pharmaceuticals |
| 04/22/2003 | US6552043 Benzimidazolinyl piperidines as CGRP ligands |
| 04/22/2003 | US6552030 Inhibit human factor Xa; treating thrombotic activity; 3-((3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-((2-(1,2 -dihydoxyethyl)-4-hydroxy-5-ethoxytetrahydrofuran-3-yl)oxy)-pyridin-2 -yl)oxy)4-hydroxybenzamidine |
| 04/22/2003 | US6552022 Atherosclerosis in a mammal, pancreatitis, non-insulin dependent diabetes mellitus, coronary heart disease in a lowering serum lipid levels |
| 04/22/2003 | US6552019 Inhibitors of p38 |
| 04/22/2003 | US6552017 Substituted heterocycle fused gamma-carbolines |
| 04/22/2003 | US6552015 Azabicycloalkane derivatives and therapeutic uses thereof |
| 04/22/2003 | US6551992 Stable insulin formulations |
| 04/22/2003 | US6551990 Methods of inhibiting ectopic calcification |
| 04/22/2003 | US6551838 Microfabricated devices for the storage and selective exposure of chemicals and devices |
| 04/22/2003 | US6551812 Diagnosing PPAR pathophysiologies, and identifying agents for treating these pathophysiologies, using nucleic acids whose expression changes following addition to cells of a ligand for PPAR |
| 04/22/2003 | US6551810 Polypeptide retains the ability to dephosphorylate an activated MAP-kinase |
| 04/22/2003 | US6551627 Medicinal herbal compounds for the prevention and treatment of diabetes |
| 04/22/2003 | CA2292673C Pharmaceutical compositions containing eletriptan hemisulphate |
| 04/22/2003 | CA2287054C 1,3,8-triazaspiro¬4,5|decanone compounds as orl1-receptor agonists |
| 04/19/2003 | CA2361863A1 Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications |
| 04/17/2003 | WO2003031939A2 Protein modification and maintenance molecules |
| 04/17/2003 | WO2003031652A1 Method of examining type i diabetes |
| 04/17/2003 | WO2003031464A2 Remodeling and glycoconjugation of peptides |
| 04/17/2003 | WO2003031459A2 Modulation of the expression of genes dependent on stat-1 |
| 04/17/2003 | WO2003031440A1 3,4-di-substituted maleimide compounds as cxc-chemokine receptor antagonists |
| 04/17/2003 | WO2003031438A1 3-[4-(substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2-indolinone derivatives as kinase inhibitors |
| 04/17/2003 | WO2003031434A1 Compounds and methods |
| 04/17/2003 | WO2003031432A1 Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor |
| 04/17/2003 | WO2003031410A1 Ligands of melanocortin receptors and compositions and methods related thereto |
| 04/17/2003 | WO2003031408A2 Tricyclic compounds useful for modulating lxr |
| 04/17/2003 | WO2003031407A2 β-LACTAMYL VASOPRESSIN VlaANTAGONISTS |
| 04/17/2003 | WO2003031400A1 Low-calcemic oxime analogs of 1alpha, 25-dihydroxy vitamin d3 |
| 04/17/2003 | WO2003030993A1 2-amino-6-(2,4,5-substituted-phenyl)-pyridines for use as nitric oxide synthase inhibitors |
| 04/17/2003 | WO2003030941A1 Controlled release drug delivery composition comprising polycationic polymer and negatively charged pharmacologically active compound |
| 04/17/2003 | WO2003030937A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists |
| 04/17/2003 | WO2003030936A1 Remedies for life style-related diseases or cibophobia and method of screening the same |
| 04/17/2003 | WO2003030922A2 Bestrophin and bestrophin homologous proteins involved in the regulation of energy homeostasis |
| 04/17/2003 | WO2003030914A1 Utilization of phosphatidylserine in the treatment of attention deficit syndrome (adhs) |
| 04/17/2003 | WO2003030912A1 Prostaglandin analogs as chloride channel opener |
| 04/17/2003 | WO2003030903A1 The use of tizanidine for treating metabolic disorders related to abnormal insulin secretion |
| 04/17/2003 | WO2003030901A1 Arylsulphonyl-substituted tetrahydro- and hexahydro-carbazoles as 5-ht-6 receptor ligands |
| 04/17/2003 | WO2003030891A1 Use of hydroxyoleic acid and similar compounds in the production of medicaments |
| 04/17/2003 | WO2003030890A1 Immune system activators |
| 04/17/2003 | WO2003030889A1 Para-amino benzoic acids as integrin antagonists |
| 04/17/2003 | WO2003030878A2 Galenic microparticulate oral formulation |
| 04/17/2003 | WO2003030876A1 Intraorally disintegrating valdecoxib compositions prepared by spray drying process |